** Animal diagnostics maker IDEXX Laboratories' IDXX.O shares down 1.2% at $406.41
** BofA Global Research cuts PT to $475 from $535 on vet visit declines
** The new PT represents a 30% upside to the stock's last close
** "IDXX's direct leverage to clinic visit volumes creates a tough setup given the weak readings through Q1 and April so far" - BofA
** Brokerage says vet visit trends "leave a little room for upside revisions"
** IDXX expects about a 2% decline in clinical visits for 2025 - co said on a Q4 conference call
** Eight of 14 brokerages rate the stock "buy" or higher, six "hold"; their median PT is $502.13 - LSEG
** Including session's move, IDXX down 1.5% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.